Chemistry:Testolone
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C20H16ClN5O2 |
| Molar mass | 393.83 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
RAD140 is an investigational selective androgen receptor modulator (SARM) developed as a future substitute of exogenous Testosterone replacement therapy (TRT). Some of the benefits under investigation are for the treatment of conditions such as muscle wasting and skeleton wasting (Osteoporosis). It was later shown to suppress the growth of breast cancer models that are positive for both androgen and estrogen receptors (AR/ER+). RAD140 was discovered and initially developed by Radius Health, Inc. (RDUS). The first-in-human study was initiated in 2017 in patients with breast cancer. It was licensed to Ellipses Pharmaceuticals in 2020.[1][2][3][4]
In early 2020 a single case report of drug-induced liver injury following use of RAD 140 was published. [5] RAD 140 is still in the first stage of clinical trials with the results expected in late 2020. When released these trials will share the safety, toxicity and potential adverse effects of RAD 140.
Animal studies
According to a study conducted by researchers at the University of Southern California, Los Angeles, RAD 140 appears to be safer than testosterone replacement therapy (TRT) in rats. Further research is required to determine if RAD 140 is also safer than TRT in human subjects. [6]
Another study conducted in February 2011 found that RAD 140 slightly increased lean muscle mass when used in primate subjects, by targeting androgen receptors in skeletal tissue. These measured increases in lean muscle mass were not statistically significant, however, this may be due to the small group sizes (n = 3) and relatively large standard deviations.[7]
See also
References
- ↑ "Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats". Endocrinology 155 (4): 1398–406. April 2014. doi:10.1210/en.2013-1725. PMID 24428527.
- ↑ "Androgens increase survival of adult-born neurons in the dentate gyrus by an androgen receptor-dependent mechanism in male rats". Endocrinology 154 (9): 3294–304. September 2013. doi:10.1210/en.2013-1129. PMID 23782943.
- ↑ "Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140". ACS Medicinal Chemistry Letters 2 (2): 124–9. February 2011. doi:10.1021/ml1002508. PMID 24900290.
- ↑ "Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action". Clinical Cancer Research 23 (24): 7608–7620. December 2017. doi:10.1158/1078-0432.CCR-17-0670. PMID 28974548.
- ↑ Flores, Joan Ericka; Chitturi, Shivakumar; Walker, Sarah (2020). "Drug‐Induced Liver Injury by Selective Androgenic Receptor Modulators". Hepatology Communications 4 (3): 450–452. doi:10.1002/hep4.1456. ISSN 2471-254X. PMID 32140660.
- ↑ "Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats". Endocrinology 155 (4): 1398–406. April 2014. doi:10.1210/en.2013-1725. PMID 24428527.
- ↑ "Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140". ACS Medicinal Chemistry Letters 2 (2): 124–9. February 2011. doi:10.1021/ml1002508. PMID 24900290.
 |
